Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
200 participants
INTERVENTIONAL
2011-08-31
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange
NCT00568347
A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations
NCT00116402
Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)
NCT03535870
Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD
NCT01209715
Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease
NCT00975195
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LIPO-102, Low
salmeterol xinafoate, fluticasone propionate
LIPO-102
LIPO-102, Mid
salmeterol xinafoate, fluticasone propionate
LIPO-102
LIPO-102, High
salmeterol xinafoate, fluticasone propionate
LIPO-102
LIPO-102; Placebo
Placebo
Placebo
salmeterol xinafoate
salmeterol xinafoate
Salmeterol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
salmeterol xinafoate, fluticasone propionate
LIPO-102
Placebo
Placebo
salmeterol xinafoate
Salmeterol
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* abdominal contour defect
* BMI \<25 kg/msq
* Stable diet and exercise and body weight
Exclusion Criteria
* Known hypersensitivity to study drugs
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Neothetics, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Murray Maytom
Role: STUDY_DIRECTOR
Neothetics, Inc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beverly Hills, California, United States
San Diego, California, United States
New York, New York, United States
Raleigh, North Carolina, United States
Nashville, Tennessee, United States
Plano, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LIPO-102-CL-11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.